# A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722

> **NCT02346890** · PHASE1 · COMPLETED · sponsor: **Ardelyx** · enrollment: 16 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** AZD1722
- **DRUG:** Renvela

## Key facts

- **NCT ID:** NCT02346890
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2013-04
- **Final completion:** 2013-04
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2015-01-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02346890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02346890, "A Phase 1 Study to Examine the Effect of Renvela on the Pharmacodynamics of AZD1722". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02346890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*